论文部分内容阅读
本研究旨在探讨G-CSFR IV型异构体在成年急性白血病患者中的表达及其临床意义。以19例正常骨髓造血干细胞为对照,利用定量RT-PCR检测正常对照、99例成年AML和34例ALL患者的G-CSFR IV/G-CSFR I型异构体的相对表达水平,并对其中84例AML(非M3)患者的临床特征及化疗效果进行分析。结果表明,GCSFR IV/G-CSFR I相对表达水平在AML患者较ALL患者及正常造血干细胞组高,而G-CSFR IV/G-CSFR I的相对表达水平在ALL患者组与正常造血干细胞组差别无统计学意义。AML(非M3)患者的临床特征及疗效分析显示,G-CSFR IV/G-CSFR I相对高表达的患者比低表达的患者的临床CR率低。G-CSFR IV/G-CSFR I相对表达水平与AML(非M3)患者的性别、年龄、幼稚细胞比例、FAB分型、染色体和融合基因所作的危险分层之间无相关性。结论:G-CSFR IV异构体异常高表达与急性髓系白血病预后差相关。
This study aimed to investigate the expression of G-CSFR IV isoforms in adult patients with acute leukemia and its clinical significance. Nineteen normal bone marrow hematopoietic stem cells served as controls, and the relative expression levels of G-CSFR IV / G-CSFR I isoforms in normal controls, 99 adult AML patients and 34 ALL patients were detected by quantitative RT-PCR. Eighty-four patients with AML (non-M3) were analyzed for clinical features and chemotherapeutic efficacy. The results showed that the relative expression level of GCSFR IV / G-CSFR I was higher in AML patients than in ALL patients and in normal hematopoietic stem cells group. The relative expression level of G-CSFR IV / G-CSFR I was different between ALL patients and normal hematopoietic stem cells No statistical significance. Clinical characteristics and efficacy analyzes of AML (non-M3) patients show that patients with relatively high G-CSFR IV / G-CSFR I have a lower clinical CR rate than patients with low expression. G-CSFR IV / G-CSFR I relative expression levels and AML (non-M3) patients with gender, age, naive cell ratio, FAB typing, chromosomal and fusion gene risk stratification made no correlation. Conclusion: The abnormally high expression of G-CSFR IV isoforms correlates with the poor prognosis of acute myeloid leukemia.